Cargando…
Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial
BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Her...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533952/ https://www.ncbi.nlm.nih.gov/pubmed/26265479 http://dx.doi.org/10.1186/s40360-015-0021-1 |
_version_ | 1782385387349475328 |
---|---|
author | Holz, Olaf Biller, H. Mueller, M. Kane, K. Rosano, M. Hanrahan, J. Hava, D. L. Hohlfeld, J. M. |
author_facet | Holz, Olaf Biller, H. Mueller, M. Kane, K. Rosano, M. Hanrahan, J. Hava, D. L. Hohlfeld, J. M. |
author_sort | Holz, Olaf |
collection | PubMed |
description | BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers. METHODS: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure. RESULTS: Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p ≤ 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14 + cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated. CONCLUSION: Ozone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01690949. Registered 12 September 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0021-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4533952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45339522015-08-13 Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial Holz, Olaf Biller, H. Mueller, M. Kane, K. Rosano, M. Hanrahan, J. Hava, D. L. Hohlfeld, J. M. BMC Pharmacol Toxicol Research Article BACKGROUND: The ozone challenge model can be used to assess the efficacy of anti-inflammatory compounds in early phases of clinical drug development. PUR118, a calcium salt based formulation engineered in the iSPERSE(TM) dry powder delivery technology, is a novel anti-inflammatory drug for COPD. Here we evaluated the efficacy and safety of three doses of PUR118 in attenuating ozone-induced airway inflammation in healthy volunteers. METHODS: In a single-blind, phase 1B proof of concept study, 24 subjects were enrolled to sequentially receive three doses of PUR118 (5.5 mg, n = 18; 11.0 mg, n = 18; 2.8 mg, n = 16). Each dose was inhaled 3 times (1, 13, 25 h, preceded by 2 puffs salbutamol) before the ozone exposure (250 ppb, 3 h intermittent exercise). Sputum was induced 3 h after the end of exposure. RESULTS: Sputum neutrophils, sputum CD14+ cells, as well as concentrations of IL1B, IL6, IL8, MMP9, and TNFA in sputum supernatant significantly increased after ozone exposure (n = 24). The percentage of sputum neutrophils (n = 12 who completed all treatments) did not change following treatment with different doses of PUR118. The high dose treatment group (n = 16) showed a decrease in the percentage and number of sputum macrophages (p ≤ 0.05) as well as a decrease in blood neutrophils (p = 0.04), and an increase in blood CD14 + cells (p = 0.04) compared to baseline. All dosages of PUR118 were safe and well tolerated. CONCLUSION: Ozone challenge resulted in the expected and significant increase of sputum inflammatory parameters. Treatment with multiple rising doses of PUR118 was safe and three applications within 25 h prior to the ozone challenge had small effects on ozone-induced airway inflammation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01690949. Registered 12 September 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40360-015-0021-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-12 /pmc/articles/PMC4533952/ /pubmed/26265479 http://dx.doi.org/10.1186/s40360-015-0021-1 Text en © Holz et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Holz, Olaf Biller, H. Mueller, M. Kane, K. Rosano, M. Hanrahan, J. Hava, D. L. Hohlfeld, J. M. Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title | Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title_full | Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title_fullStr | Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title_full_unstemmed | Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title_short | Efficacy and safety of inhaled calcium lactate PUR118 in the ozone challenge model - a clinical trial |
title_sort | efficacy and safety of inhaled calcium lactate pur118 in the ozone challenge model - a clinical trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533952/ https://www.ncbi.nlm.nih.gov/pubmed/26265479 http://dx.doi.org/10.1186/s40360-015-0021-1 |
work_keys_str_mv | AT holzolaf efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT billerh efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT muellerm efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT kanek efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT rosanom efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT hanrahanj efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT havadl efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial AT hohlfeldjm efficacyandsafetyofinhaledcalciumlactatepur118intheozonechallengemodelaclinicaltrial |